Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Clinton’s Drug Plan Embraces CER-Driven Pricing ‘Accountability’

This article was originally published in The Pink Sheet Daily

Executive Summary

Think tank report that informed the plan suggests impact of CER reviews could be bolstered by use of NIH "march-in" rights if prices stay "unreasonably" high despite review conclusions.

Advertisement

Related Content

Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Clinton Transition Team Includes Tanden, Underscoring Rx Pricing Focus
NIH Resists “March In” On Norvir Patents Based On Pricing Concerns

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel